Prospective Alzheimer’s disease trials yield disappointing results for GLP-1
(MedPage Today) – Novo Nordisk announced Monday that the oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow the progression of Alzheimer’s disease in the long-awaited phase 3 trial of EVOKE. The company shared key results from two years…